ArticleScientific reports2012
A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs.
Article in Scientific reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Multiplexed iPSC platform for advanced NK cell immunotherapies.Cell reports. Medicine · 2025Review
- Article
- A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors.Cell reports. Medicine · 2025Article
- Article
- Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.Lancet (London, England) · 2025Article
- Review
- Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies.Cell stem cell · 2024Article
- Advances in physiological and clinical relevance of hiPSC-derived brain models for precision medicine pipelines.Frontiers in cellular neuroscience · 2024Review
- A chemical approach facilitates CRISPRa-only human iPSC generation and minimizes the number of targeted loci required.Future science OA · 2024Article
- NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.Current hematologic malignancy reports · 2023Review
- A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.Med (New York, N.Y.) · 2023Article
- Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.International journal of molecular sciences · 2023Article
- Review
- Article
- Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.Nature biomedical engineering · 2022Article
- Current Progress of CAR-NK Therapy in Cancer Treatment.Cancers · 2022Review
- An allied reprogramming, selection, expansion and differentiation platform for creating hiPSC on microcarriers.Cell proliferation · 2022Article
- Development of an efficient single-cell cloning and expansion strategy for genome edited induced pluripotent stem cells.Molecular biology reports · 2022Article
- Rapid and Highly Efficient Isolation and Purification of Human Induced Pluripotent Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.